DHS 157.67 NoteNote: Specialty boards whose certification processes have been recognized by the Department, the NRC or an agreement state will be posted on the NRC’s web site at www.nrc.gov.
DHS 157.67(17)(b)(b) Has completed a structured educational program in basic radionuclide techniques applicable to the use of a sealed source in a therapeutic medical unit that includes all of the following:
DHS 157.67(17)(b)1.1. Two hundred hours of classroom and laboratory training in all the following areas:
DHS 157.67(17)(b)1.a.a. Radiation physics and instrumentation.
DHS 157.67(17)(b)1.b.b. Radiation protection.
DHS 157.67(17)(b)1.c.c. Mathematics pertaining to the use and measurement of radioactivity.
DHS 157.67(17)(b)1.d.d. Radiation biology.
DHS 157.67(17)(b)2.2. Five hundred hours of work experience, under the supervision of an authorized user who meets the requirements in this subsection, s. DHS 157.61 (10), or equivalent NRC or agreement state requirements at a medical facility authorized to use byproduct materials under sub. (1), involving all of the following:
DHS 157.67(17)(b)2.a.a. Reviewing full calibration measurements and periodic spot checks.
DHS 157.67(17)(b)2.b.b. Preparing treatment plans and calculating treatment doses and times.
DHS 157.67(17)(b)2.c.c. Using administrative controls to prevent a medical event involving the use of radioactive material.
DHS 157.67(17)(b)2.d.d. Implementing emergency procedures to be followed in the event of the abnormal operation of the medical unit or console.
DHS 157.67(17)(b)2.e.e. Checking and using survey meters.
DHS 157.67(17)(b)2.f.f. Selecting the proper dose and how it is to be administered.
DHS 157.67(17)(b)3.3. Three years of supervised clinical experience in radiation therapy under an authorized user who meets the requirements in this subsection, s. DHS 157.61 (10), or equivalent NRC or agreement state requirements, as part of a formal training program approved by the Residency Review Committee for Radiation Oncology of the Accreditation Council for Graduate Medical Education or Royal College of Physicians and Surgeons of Canada or the Committee on Postdoctoral Training of the American Osteopathic Association. This experience may be obtained concurrently with the supervised work experience required by subd. 2.
DHS 157.67(17)(b)4.4. A written attestation obtained under sub. (18).
DHS 157.67(18)(18)Written attestation. A licensee shall require an authorized user of a sealed source for a use authorized under sub. (17) to have obtained written attestation that the individual has successfully completed the requirements in sub. (17) (b), and has achieved a level of competency sufficient to function independently as an authorized user of each type of therapeutic medical unit for which the individual is requesting authorized user status. The attestation must be obtained from either of the following:
DHS 157.67(18)(a)(a) A preceptor authorized user who meets the requirements in sub. (17), s. DHS 157.61 (10), or equivalent NRC or agreement state requirements for an authorized user for each type of therapeutic medical unit for which the individual is requesting authorized user status.
DHS 157.67(18)(b)(b) . A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in sub. (17), s. DHS 157.61 (10), or equivalent NRC or agreement state requirements user for each type of therapeutic medical unit for which the individual is requesting authorized user status. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in sub. (17) (b).
DHS 157.67 HistoryHistory: CR 01-108: cr. Register July 2002 No. 559, eff. — see Note at the start of the chapter; correction in (4) (f) made under s. 13.93 (2m) (b) 7., Stats., Register July 2002 No. 559; CR 06-021: am. (9) (b) 2., 3., 6., 8. and 10., r. and recr. (17), cr. (18) Register September 2006, No. 609, eff. 10-1-06; CR 09-062: am. (8) (b) 1., (17) (b) 2. (intro.), 3. and (18) Register April 2010 No. 652, eff. 5-1-10; CR 16-078: am. (11) (f), (12) (b) 3. Register January 2018 No. 745, eff. 2-1-18; CR 22-015: r. (1) (intro.), renum. (1) (a) to (1) (a) (intro.) and am., cr. (1) (a) 1., renum. (1) (b) to (1) (a) 2. and am., cr. (1) (b), am. (4) (d) (intro.), (e), cr. (4) (g), (h), am. (15) (title), (a), (17) (intro.), (a) (intro.), 1., (b) 2. (intro.), 3., cr. (17) (b) 4., renum. (18) to (18) (intro.) and am., cr. (18) (a), (b) Register June 2023 No. 810, eff. 7-1-23; correction in numbering of (4) (h) made under s. 13.92 (4) (b) 1., Stats., Register June 2023 No. 810.
DHS 157.68DHS 157.68Radioactive drugs for medical use.
DHS 157.68(1)(1)Preparation. A licensee authorized to manufacture, prepare or transfer for commercial distribution or noncommercial transfer to medical use licensees in a consortium radioactive drugs shall ensure that any individual preparing the drugs is one of the following:
DHS 157.68(1)(a)(a) An authorized nuclear pharmacist.
DHS 157.68(1)(b)(b) An individual under the supervision of an authorized nuclear pharmacist.
DHS 157.68(1)(c)(c) A pharmacist that meets any of the following criteria:
DHS 157.68(1)(c)1.1. The requirements for an authorized nuclear pharmacist as specified in s. DHS 157.61 (9) and (11).
DHS 157.68(1)(c)2.2. Is identified as an authorized nuclear pharmacist on a license issued by the department, an agreement state or the NRC.
DHS 157.68(1)(c)3.3. Is identified as an authorized nuclear pharmacist by a licensee who is authorized by the department, an agreement state or the NRC to designate authorized nuclear pharmacists operating under their license.
DHS 157.68(1)(c)4.4. Functioned as a nuclear pharmacist preparing only radioactive drugs containing accelerator-produced radioactive material, and practiced at a pharmacy at a government agency or federally recognized Indian Tribe before November 30, 2007 or at all other locations of use before August 8, 2009.